What is the recommended dosing and titration protocol for acenocoumarol in adults?

Acenocoumarol Dosing and Titration Protocol

For adults requiring acenocoumarol anticoagulation, initiate therapy with 3 mg daily and titrate based on INR monitoring to achieve a target range of 2.0-3.0, with dose adjustments made in 10-20% increments depending on INR values. 1

Initial Dosing

• Starting dose: 3 mg daily for acenocoumarol in adults 1
• Administer once daily, preferably at the same time each day 1
• Bridge with heparin (UFH or LMWH) for acute thrombotic conditions until therapeutic INR is achieved for 2 consecutive days, as peak anticoagulation effect is not reached until 5-7 days after initiation 1

Target INR Range

• Maintain INR between 2.0-3.0 for most indications including venous thromboembolism and atrial fibrillation 1
• Aim for an INR value of 2.5 to maximize time in therapeutic range 1
• INR <2.0 increases thromboembolism risk, while INR >3.0 (especially >3.5) significantly increases major bleeding risk, particularly intracranial hemorrhage 1

Dose Titration Protocol

Follow this structured algorithm based on INR values 1:

For INR 1.1-1.4:

• Increase dose by 20% 1

For INR 1.5-1.9:

• Increase dose by 10% 1

For INR 2.0-3.0:

• No change - maintain current dose 1

For INR 3.1-3.5:

• Decrease dose by 10% 1

For INR >3.5:

• Hold acenocoumarol until INR <3.5, then restart at 20% dose reduction 1

For INR >10:

• Reverse with oral vitamin K 1
• For major bleeding at any INR level, reverse rapidly with IV vitamin K plus activated prothrombin concentrate 1

Monitoring Schedule

• Check INR daily until therapeutic range (2.0-3.0) is achieved 1
• Once stable, check 2-3 times weekly during the first 2 weeks 1
• Then weekly for the next few weeks 1
• During long-term maintenance, frequency can be reduced to every 4 weeks if INR remains stable 1
• Recheck more frequently with any illness, medication changes, or dietary modifications 1

Time in Therapeutic Range (TTR) Considerations

• Target TTR ≥65% for optimal outcomes 1
• If TTR <65%, implement additional measures: more frequent INR testing, review medication adherence, address factors influencing INR control, and provide education/counseling 1
• Consider switching to direct oral anticoagulants (DOACs) if TTR remains consistently low despite interventions 1

Dose Increment Precision

• Standard dosing uses 1.0 mg increments for most patients 2
• For elderly patients (≥80 years) on low doses (0.5-2 mg daily), 0.5 mg increments may be considered, though this provides only marginal TTR improvement (approximately 2-4% absolute increase) and carries increased risk of dosing errors 2
• The clinical benefit of more precise dosing is minimal and may be offset by medication error risk 2

Drug Interactions

Critical warning: Barbiturates (including phenobarbital) induce hepatic microsomal enzymes, resulting in increased acenocoumarol metabolism and decreased anticoagulant effect 3

• Patients stabilized on acenocoumarol require dosage adjustments if barbiturates are added or withdrawn 3
• Monitor INR closely and adjust doses accordingly 3

Special Populations

Elderly Patients:

• May require lower maintenance doses due to age-related pharmacokinetic changes 2
• Monitor more closely for bleeding complications 2

Hepatic Impairment:

• Use with extreme caution; consider reduced initial doses 3
• More frequent monitoring required 3

Common Pitfalls to Avoid

• Never use loading doses - start with expected maintenance dose of 3 mg daily 1
• Do not extrapolate dosing from warfarin - acenocoumarol has a shorter half-life (9 hours vs 42 hours for warfarin) requiring different management 1
• Avoid premature discontinuation of heparin bridging - continue until INR is therapeutic for 2 consecutive days 1
• Do not make dose adjustments based on single INR values - consider trends and clinical context 1